B-Cell Targeted Carfilzomib Desensitization

This study is a non-randomized, open label, iterative pilot study. The duration of study will
include a 16 month enrollment period and 5 to 6 months of follow-up. A total of 32 patients,
male and female, between the ages 18 to 65 will be enrolled.

Inclusion Criteria:

1. Patient is between 18 and 65 years of age, inclusive.

2. Voluntary written informed consent.

3. Female subject is either postmenopausal for at least 1 year prior to initiation of
study treatment, is surgically sterilized, or if of childbearing potential, agrees to
practice 2 effective methods of contraception through 3 months after the last dose of
carfilzomib.

4. Male subjects, even if surgically sterilized (i.e. status post-vasectomy) must agree
to 1 effective contraception.

5. Patient with eligible living donor will have: 1) positive cytotoxic crossmatch, or 2)
moderate to strongly positive T or B cell flow cytometry crossmatch (with confirmed
donor-specific antibodies (DSAs) on solid-phase assay at screening, or 3) > 2 low to
moderate level DSAs (DSA value from 1500 - 8000 MFI).

6. LVEF ≥ 45% within 3 months of evaluation.

7. Patient that is on the kidney transplant waiting list awaiting a deceased donor
transplant and has a current or peak cytotoxic or calculated panel reactive antibody
(PRA) > 30%.

8. Patient must have no known contraindications to treatment with carfilzomib or
rituximab.

9. Review of pre-transplant medical clearance by the patient's dialysis nephrologist or
transplant nephrologist or treating physician to assure the patient is medically
acceptable for study entry.

10. Patient must be vaccinated against hepatitis B virus.

Exclusion Criteria:

1. Patient has significant neuropathy (Grades 3 - 4, or Grade 2 with pain) by CTCAE
criteria within 14 days before enrollment.

2. Myocardial infarction within 6 months prior to enrollment or has ADQI Heart Failure in
ESRD Classification System Class 2NR or greater (Appendix B), uncontrolled angina,
severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia or active conduction system abnormalities.

3. Patient has received other investigational drugs within 14 days prior to initiation of
study treatment.

4. Serious medical or psychiatric illness likely to interfere with participation in this
clinical study.

5. Diagnosed or treated for another malignancy within 2 years of enrollment, with the
exception of: 1) complete resection of basal cell carcinoma or squamous cell carcinoma
of the skin, 2) an in situ malignancy, 3) low-risk prostate cancer after curative
therapy, or 4) any cancer with a cure rate ≥ 99%.

6. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
antibodies.

7. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize
carfilzomib)

8. Patients with a hemoglobin count <8 g/dL (80 g/L) (subjects may be receiving red blood
cell [RBC] transfusions in accordance with institutional guidelines), absolute
neutrophil count < 1,000/mm3 or platelet count < 75,000/mm3 within 14 days of consent.

9. Patients who are anti-HIV-positive, or HBsAg-positive, or anti-HCV positive with a
detectable HCV viral load on testing performed within one year of consent.

10. Patients with current or recent severe systemic infections requiring treatment
(systemic antibiotics, antivirals, or antifungals) within the 2 weeks prior to
initiation of study treatment.

11. Receipt of a live vaccine within 4 weeks prior to initiation of study treatment.

12. Evidence of severe liver disease by medical history or physical exam with abnormal
liver profile (aspartate aminotransferase [AST], alanine aminotransferase [ALT] or
total bilirubin > 1.5 times upper limit of normal [ULN]) on testing performed within
30 days of consent.

13. Female subject is pregnant or breast-feeding.

14. Any other clinically significant medical disease or condition that, in the
Investigator's opinion, may interfere with protocol adherence or a subject's ability
to give informed consent.

15. Patient is not yet on dialysis.